PF-05230905 / Sanofi - LARVOL DELTA

Ablynx regains rights from Pfizer to Nanobodies targeting TNF-alpha (Ablynx) - Ablynx announced that it has regained worldwide rights from Pfizer to develop and commercialize Nanobodies targeting TNF-alpha; These rights include the product ATN-103 & PF-05230905; Ablynx will undertake a detailed review of the programs before deciding how to proceed

Collaboration termination • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis

Annual Report '11 (Ablynx) - ATN -192 / Ablynx; Anticipated data for P1 trial for RA in H1 2012

Anticipated P1 data • Rheumatoid Arthritis